Axsome Therapeutics (AXSM) vs Cytokinetics (CYTK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Axsome Therapeutics (AXSM) has outperformed Cytokinetics (CYTK) over the past year, gaining 43.3% versus a gain of 2.0%. Over five years, AXSM leads with a +324.1% price change compared with +68.1% for CYTK. Axsome Therapeutics is the larger company by market cap ($8.91 billion vs $8.62 billion), about 1.0 times the size, while Cytokinetics is growing revenue faster (+376.6% vs +65.5%).
Axsome Therapeutics converts more of its revenue into profit, with a net margin of -28.7% versus -891.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AXSM | CYTK |
|---|---|---|
| Share price | $170.08 | $62.01 |
| Market cap | $8.91B | $8.62B |
| 1-day change | -1.67% | +1.46% |
| YTD return | -6.88% | -2.41% |
| 1-year return | +43.27% | +1.96% |
| 5-year return | +324.14% | +68.09% |
| Forward P/E | 36.17 | — |
| EPS (TTM) | $-3.74 | $-7.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $638.50M | $88.04M |
| Revenue growth (YoY) | +65.55% | +376.56% |
| Net income (latest FY) | $-183.17M | $-784.96M |
| Gross margin | 92.56% | — |
| Operating margin | -26.12% | -695.44% |
| Net margin | -28.69% | -891.60% |
| 52-week high | $260.19 | $88.31 |
| 52-week low | $119.20 | $54.30 |
| Distance from 52-week high | -34.63% | -29.78% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +67.35% | +77.23% |
| Average volume | 712.30K | 1.97M |
| Shares outstanding | 52.38M | 139.02M |
| Employees | 1,346 | 673 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AXSM has outperformed CYTK by 41.3 percentage points over the past year.
- Axsome Therapeutics is more profitable, keeping -28.7 cents of every revenue dollar as net income versus -891.6 cents for Cytokinetics.
- Cytokinetics grew revenue faster in its latest fiscal year (+376.56% vs +65.55%).
About Axsome Therapeutics
AXSM stock →Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,346 employees
About Cytokinetics
CYTK stock →Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
Health Care · Biotechnology: Pharmaceutical Preparations · 673 employees
AXSM vs CYTK FAQ
Which is bigger, Axsome Therapeutics or Cytokinetics?
Axsome Therapeutics (AXSM) is larger, with a market capitalization of $8.91B compared with $8.62B for Cytokinetics (CYTK).
Which stock has performed better over the past year, AXSM or CYTK?
AXSM returned +43.27% over the past 12 months, compared with +1.96% for CYTK (price return, excluding dividends). Past performance does not predict future results.
Are Axsome Therapeutics and Cytokinetics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.